联邦制药品牌怎么样 申请店铺

我要投票 联邦制药在连锁药店行业中的票数:359 更新时间:2025-06-07
联邦制药是哪个国家的品牌?「联邦制药」是 珠海联邦制药股份有限公司 旗下著名品牌。该品牌发源于广东,由创始人蔡海山在1993-07-03期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力联邦制药品牌出海!将品牌入驻外推网,定制联邦制药品牌推广信息,可以显著提高联邦制药产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

联邦制药怎么样

联邦制药1990年成立于香港。1994年,投资数亿港元创建珠海联邦制药股份有限公司,以先进的制药技术,科学的管理,卓越的服务,怀着为中国人民健康服务的热忱,提供多元化的产品,特别是抗菌素产品,以及该种产品的原料药和中间体,全力促进中国医药健康事业的发展。

联邦制药拥有6家生产基地,包括香港联邦制药厂有限公司(制剂)、珠海联邦制药股份有限公司(原料)、珠海联邦制药股份有限公司中山分公司(制剂)、联邦制药金亿胶囊厂(空心胶囊)、联邦制药(内蒙古)有限公司(中间体)、金桂制药有限公司(兽药)。联邦制药集药品研发、生产、经营为一体,从生物发酵开始集医药中间体、原料药、药物制剂、药包材生产为一体,实现垂直一体化的生产经营模式,以优质的售后服务网络、完善的市场信息反馈系统、严谨的质量保证体系,为联邦制药卓越的产品质量奠定了坚实的基础。2007年6月15日,联邦制药国际控股有限公司在香港成功上市,标志着联邦制药步上了一个新的发展平台,为立足香港,辐射全球,实现企业品牌的快速扩张拓展了广阔的空间。

联邦制药拥有世界一流的生产设备。年生产能力为胶囊剂15.4亿粒,片剂10.8亿片,颗粒剂1.15亿袋,混悬剂2000万袋,口服液2000万瓶,粉针剂1.3亿瓶,软膏剂4500万支,冻干粉针1950万瓶,滴眼剂2400万支,胰岛素2400万瓶,年生产能力一举跃上新台阶。联邦制药在多个产品一路领先,国家火炬计划重点高新技术企业、广东省高新技术企业、中国制药专业博士后科研工作站、中国制药工业百强、广东省先进集体,每一个享誉业界的称号,充分证明了联邦制药的综合实力;国内首批全厂所有剂型一次性通过国家GMP认证的制药企业,160多种药物的研发,上百种医药批件的取得,每一个富有价值的金字招牌,都充分体现了联邦制药的领先水平。

联邦制药一如既往地秉承“让生命更有价值”的承诺,致力推动中国医药卫生事业的发展,为社会提供更多优质高效的医药产品。


UL was founded in Hong Kong in 1990. In 1994, the company invested hundreds of millions of Hong Kong dollars to establish Zhuhai federal Pharmaceutical Co., Ltd. with advanced pharmaceutical technology, scientific management, excellent service, with the enthusiasm of serving the Chinese people's health, to provide a wide range of products, especially antibiotic products, as well as raw materials and intermediates of this product, to promote the development of China's pharmaceutical health industry. UL has 6 production bases, including Hong Kong federal Pharmaceutical Co., Ltd. (preparations), Zhuhai federal Pharmaceutical Co., Ltd. (raw materials), Zhongshan branch of Zhuhai federal Pharmaceutical Co., Ltd. (preparations), UL Jinyi Capsule Factory (hollow capsules), UL Inner Mongolia Co., Ltd. (intermediates), Jin Gui pharmaceutical Co., Ltd. (veterinary drugs) 。 With the integration of drug research and development, production and operation, and the integration of pharmaceutical intermediates, APIs, pharmaceutical preparations and drug packaging materials from the start of biological fermentation, UL has realized the vertically integrated production and operation mode. With its high-quality after-sales service network, perfect market information feedback system and strict quality assurance system, UL has laid a solid foundation for its excellent product quality Foundation. On June 15, 2007, UL International Holdings Co., Ltd. successfully listed in Hong Kong, marking that UL has stepped onto a new development platform, expanding broad space for its foothold in Hong Kong, global radiation and rapid expansion of corporate brands. UL has world-class production facilities. The annual production capacity is 1.54 billion capsules, 1.08 billion tablets, 115 million bags of granules, 20 million bags of suspension, 20 million bottles of oral liquid, 130 million bottles of powder injection, 45 million bottles of ointment, 19.5 million bottles of lyophilized powder injection, 24 million bottles of eye drops and 24 million bottles of insulin. The annual production capacity has leaped to a new level. UL is leading the way in a number of products, including key high-tech enterprises under the national Torch Program, high-tech enterprises in Guangdong Province, postdoctoral research stations of Chinese pharmaceutical specialty, top 100 pharmaceutical enterprises in China, and advanced collective in Guangdong Province, each of which is known as the title of the industry, fully proving the comprehensive strength of UL. All the dosage forms of the first batch of the whole factory in China have passed the national GMP certification once and for all The pharmaceutical enterprises with certificates, the R & D of more than 160 kinds of drugs, the acquisition of hundreds of medical approvals, and each valuable gold brand fully reflect the leading level of UL. As always, UL adheres to the commitment of "making life more valuable", and is committed to promoting the development of China's medical and health undertakings, so as to provide more high-quality and efficient medical products for the society.

本文链接: https://brand.waitui.com/5d34d6cac.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

华晨宝马人事调整:宝思齐将出任总裁兼首席执行官,戴鹤轩返回德国任职

华晨宝马董事会今日宣布人事任命,宝思齐将自2025年8月1日起,接替戴鹤轩出任华晨宝马总裁兼首席执行官;戴鹤轩将于2025年7月31日结束其在中国的任期,返回德国,担任宝马集团首席信息官及信息技术部高级副总裁的新职务。(新浪科技)

2小时前

孩子王:拟通过控股子公司收购丝域实业100%股权

36氪获悉,孩子王发布公告,公司拟受让关联方五星控股持有的江苏星丝域65%股权。为强化产业协同和资源整合,巨子生物、自然人陈英燕、王德友拟同时受让五星控股持有的江苏星丝域10%、8%及6%的股权,本次股权转让完成后,江苏星丝域将成为公司的控股子公司,鉴于本次股权转让前江苏星丝域的注册资本尚未实缴,且无实际经营活动,本次股权转让中,公司、巨子生物、陈英燕及王德友受让江苏星丝域股权的价格均为0元。另外,公司拟通过江苏星丝域现金收购丝域实业100%股权,转让价格为16.5亿元。交易完成后,公司间接持有丝域实业65%股权,丝域实业将成为公司的控股子公司。

2小时前

美股大型科技股盘前普涨,特斯拉涨超4%

36氪获悉,美股大型科技股盘前普涨,截至发稿,特斯拉涨超4%,亚马逊涨超2%,谷歌、Meta、英伟达涨超1%,苹果涨0.83%,微软涨0.56%,奈飞涨0.55%。

2小时前

热门中概股美股盘前多数下跌,新东方跌超2%

36氪获悉,热门中概股美股盘前多数下跌,新东方跌超2%,名创优品、腾讯音乐、网易、蔚来、跌超1%,阿里巴巴跌0.68%,京东跌0.55%,小鹏汽车跌0.55%,百度跌0.41%;理想汽车涨超1%,微博涨0.63%。

2小时前

香港证监会向持牌法团发出指引,预防客户帐户内的未经授权交易

36氪获悉,据香港证监会网站消息,因应近期骗徒透过仿冒诈骗流动文字讯息中的超连结发动攻击(通常称为短讯仿冒诈骗)的事故有所增加,香港证监会今天向持牌法团发出相关指引,以预防客户帐户内的未经授权交易。

2小时前

本页详细列出关于联邦制药的品牌信息,含品牌所属公司介绍,联邦制药所处行业的品牌地位及优势。
咨询